ライフサイエンスコーパス: pyrexia

1 s (AEs) with T-VEC were fatigue, chills, and pyrexia.

2 monia, febrile neutropenia, dehydration, and pyrexia.

3 vents assessed as related to KGF were due to pyrexia.

4 e dabrafenib only group; the most common was pyrexia (108 patients, 52%) in the dabrafenib and tramet

5 ma (20 patients, 11%), fatigue (14, 8%), and pyrexia (11, 6%).

6 ts were reported, with the most common being pyrexia (16 [16%] of 101 events) and orofacial dyskinesi

7 %]), convulsion (18 [23%] vs ten [26%]), and pyrexia (17 [22%] vs six [15%]).

8 most frequently reported adverse events were pyrexia (18%), hypokalemia (15%), and hypophosphatemia (

9 mmon signs and symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (1

10 ycemia (2%; one of 64 patients), and grade 1 pyrexia (2%, one of 64 patients).

11 fatigue (36/3), nausea (25/3), rash (25/3), pyrexia (20/3), and chills (20/0).

12 ilure (25 [10%]; five related to treatment), pyrexia (21 [8%]; three related to treatment), bacteraem

13 6%) had anaemia, 23 (36%) versus seven (21%) pyrexia, 22 (34%) versus six (18%) decreased appetite, 1

14 rade 3/4, 18%), followed by infection (32%), pyrexia (23%), neutropenia (23%), headache (18%), and na

15 arthralgia (33%), hyperkeratosis (27%), and pyrexia (24%).

16 The most common adverse events were pyrexia (27 [42%] vs 11 [32%]), nausea (20 [31%] vs 7 [2

17 rade >/=3%) diarrhea (40/18), nausea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased a

18 anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumonia (4 [2%]) with pacritinib

19 rrhea (including colitis) (64%), rash (58%), pyrexia (42%), nausea (38%), chills (36%), cough (33%),

20 Nausea (51.5%), fatigue (51.5%), pyrexia (42.4%), and dyspnea and thrombocytopenia (each

21 ents with stepwise dosing were tremor (48%), pyrexia (44%), fatigue (26%), and edema (26%).

22 Cough, fatigue, and pyrexia (52% each), nausea and peripheral sensory neurop

23 The most frequent AEs were pyrexia (58%), febrile neutropenia (40%), and headache (

24 In a model of yeast induced pyrexia, administration of APAP evoked a marked hypother

25 blood-milk permeability barrier followed by pyrexia and a pronounced leukocytic influx.

26 y episodes of E. coli urinary sepsis causing pyrexia and a raised creatinine level.

27 th the most common (>/=5% of patients) being pyrexia and autoimmune haemolytic anaemia (seven [7%] ea

28 vents that were possibly study-drug related: pyrexia and intraocular inflammation that resolved with

29 ion site reactions, influenza-like symptoms, pyrexia, and headache.

30 on AEs in >or= 20% of patients were fatigue, pyrexia, and headache; most were grade 1 or 2.

31 on adverse events with IGIV-C were headache, pyrexia, and hypertension.

32 ommon adverse events were headache, fatigue, pyrexia, and influenza-like illness at 12 weeks (95 [37%

33 logic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue,

34 mon grade 1 to 2 toxicities were stomatitis, pyrexia, and nausea, whereas grade 3 and 4 toxicities we

35 influenza B infection), one life-threatening pyrexia, and ten events that led to hospital admission.

36 facial diplegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack

37 The most common adverse events were fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral n

38 This may account for anecdotal reports of pyrexia following treatment and may be significant in te

39 verse events related to study treatment were pyrexia for dabrafenib (eight [6%] of 125 patients) and

40 s of an epigastric swelling and undocumented pyrexia for four months was referred for sonographic eva

41 coded term for non-serious events (29%), and pyrexia for non-fatal serious events (38%).

42 oid arthritis for the treatment subgroup and pyrexia for the prevention subgroup.

43 o patients) grade 3 or 4 adverse events were pyrexia (four [11%]), alanine aminotransferase increase

44 nine aminotransferase increase (five [14%]), pyrexia (four [11%]), aspartate aminotransferase increas

45 regardless of study drug relationship, were pyrexia (four [3%] of 125) and headache (three [2%]).

46 The most frequent AE during treatment was pyrexia (grade 1 or 2, 75%; grade 3, 6%).

47 , disrupting negative geotaxis (painless and pyrexia), hearing (nompC), or both (nanchung and inactiv

48 Endpoints were postoperative pyrexia, ileus, wound infection, intra-abdominal abscess

49 rted in 32 (56%) of 57 patients and included pyrexia in nine (16%), anaemia in three (5%), confusiona

50 most common adverse events were headache and pyrexia, mostly mild, and reported in 20% and 13% of the

51 s in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain.

52 8 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred in >/= 10% of patients

53 t adverse events in the olesoxime group were pyrexia (n=34), cough (n=32), nasopharyngitis (n=25), an

54 In the double-blind phase, headache, pyrexia, nasopharyngitis, sleep disorder, and tremor wer

55 e some features of Chagas's disease, such as pyrexia, neuroprotection, and fibrosis, and might result

56 e dabrafenib-only group (2% vs. 9%), whereas pyrexia occurred in more patients (51% vs. 28%) and was

57 ical suspicion of GvHD (skin rash, diarrhea, pyrexia, pancytopenia, or anemia, without an obvious alt

58 puts via Drosophila TRPA channels, TRPA1 and Pyrexia (Pyx).

59 bone pain, diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomi

60 ment center with minor illnesses and without pyrexia served as controls.

61 This might explain the observed link between pyrexia, severe stroke and poor outcome.

62 ly to explain the relationship between early pyrexia, severe stroke and poor outcome.

63 The most common serious adverse events were pyrexia (six [12%]), febrile neutropenia (five [10%]), l

64 Pyrexia (six patients [2%]) and dehydration (five patien

65 group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal results on liver-funct

66 common serious adverse event (any grade) was pyrexia (three [4%] patients).

67 subpopulations of neurons, and the TRPA gene pyrexia was expressed in cap cells that may interact wit

68 The rate of pyrexia was increased with combination therapy, whereas

69 19% receiving monotherapy (P=0.09), whereas pyrexia was more common in the combination 150/2 group t

70 veloping any grade >/=2 influenza symptom or pyrexia, was not achieved, TCN-032-treated subjects show

71 orted serious adverse events; haemolysis and pyrexia were the most common (each occurring in two [5%]

72 ncluding febrile neutropenia, pneumonia, and pyrexia, were more common in the idelalisib group (140 [